Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Androfen Calculations Off Target For Reasonable Interpretations Of Claim – ERSP

This article was originally published in The Tan Sheet

Executive Summary

Androfen should discontinue claims its testosterone-boosting supplement can “reduce body fat by over 200%” because consumers can interpret it in a way that is not supported, ERSP says. The firm can continue to claim the fenugreek product enhances libido and promotes body fat loss.

Related Content

Topics

UsernamePublicRestriction

Register

PS107175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel